News Enliven Therapeutics, Inc.

Equities

ELVN

US29337E1029

Market Closed - Nasdaq Other stock markets 01:29:52 31/05/2024 am IST			5-day change	1st Jan Change
22.57 ^USD	+5.86%		-1.78%	+63.08%

20/05	Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing	MT
14/05	Enliven Therapeutics Q1 Loss Narrows	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Enliven Therapeutics to Present at Two Upcoming Investor Conferences	30/05	AQ
Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing	21/05	MT
Enliven Therapeutics Q1 Loss Narrows	15/05	MT
Enliven Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update	15/05	AQ
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	11/04	AQ
Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	11/04	CI
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors	10/04	AQ
Enliven Therapeutics, Inc. Appoints Lori Kunkel to Board of Directors	10/04	CI
Mizuho Securities Initiates Enliven Therapeutics With Buy Rating, Price Target is $34	09/04	MT
Enliven Therapeutics, Inc. announced that it has received $90.000014 million in funding	03/04	CI
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024	29/03	AQ
North American Morning Briefing : Investors -2-	21/03	DJ
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates	19/03	AQ
Enliven Therapeutics, Inc. announced that it expects to receive $90.000014 million in funding	19/03	CI
Enliven Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	15/03	AQ
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/03	CI
Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference	28/02	AQ
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to NASDAQ Biotechnology Index	18/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Enliven Therapeutics, Inc.

Equities

ELVN

US29337E1029

Summary

Filters